Literature DB >> 11375786

Cancer in the mothers and siblings of testicular cancer patients.

C D Bajdik1, N Phillips, S Huchcroft, G B Hill, R P Gallagher.   

Abstract

Some families seem to have an increased risk of several different cancers and a reduced risk of others. Either genetic predisposition or a shared environment may explain this familial clustering, and the type of cause can affect how family members should be advised. We used data from a case-control study to examine the risk of cancer in the mother, sisters and brothers of men with testicular cancer. Our results show a significant relative risk (RR=1.7; 95% confidence interval (CI): 1.05-2.6) of cancer for sisters of testicular cancer patients in comparison with the sisters of controls. When data were combined for brothers and sisters, the RR for all cancers was 1.53 (CI: 1.1-2.3). Despite the limitations of our data, there is evidence for cancer clustering in the families of testicular cancer patients. Unfortunately, the evidence is consistent with either a genetic or environmental etiology.

Entities:  

Mesh:

Year:  2001        PMID: 11375786

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  3 in total

Review 1.  Clinical epidemiology of testicular germ cell tumors.

Authors:  K-P Dieckmann; U Pichlmeier
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

2.  Risk of cancer in first- and second-degree relatives of testicular germ cell tumor cases and controls.

Authors:  Victoria M Chia; Yan Li; Lynn R Goldin; Barry I Graubard; Mark H Greene; Larissa Korde; Mark V Rubertone; Ralph L Erickson; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

3.  Nontesticular cancers in relatives of testicular germ cell tumor (TGCT) patients from multiple-case TGCT families.

Authors:  Mary L McMaster; Ketil R Heimdal; Jennifer T Loud; Janet S Bracci; Philip S Rosenberg; Mark H Greene
Journal:  Cancer Med       Date:  2015-04-17       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.